Low prices often mean low purity, contaminants, or incorrect peptide sequences
How it helps disc herniation specifically: Upregulates tendon-related growth factors BPC-157 activates the Egr-1 transcription factor, which drives collagen synthesis in fibrous tissue including the annulus fibrosus Promotes angiogenesis increases VEGF expression, improving blood supply to the avascular disc environment Neuroprotective effects multiple rodent studies show BPC-157 accelerates peripheral nerve regeneration and protects against nerve compression injury Systemic anti-inflammatory suppresses pro-inflammatory cytokine cascades without the immunosuppressive side effects of steroids Protocol: Dose: 250500mcg/day subcutaneous injection Injection site: Lower abdomen or closest accessible subQ site to the injury (though systemic distribution means proximity matters less than for localized joint issues) Duration: 68 weeks loading phase, reassess at week 8 Most people notice reduced nerve pain and improved mobility within 24 weeks
Richardson, D
Studies involving angiogenesis processes
One should not use AOD-9604 if they: Are pregnant or breastfeeding Are a minor Have a current or recent history of cancer (particularly hormone-sensitive cancers) Have uncontrolled diabetes or significant insulin resistance Have active thyroid disease that is not well-managed Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds Comprehensive labs including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels should be run before starting any peptide therapy and monitored regularly throughout
Both reach the same 12mg maintenance dose but on different timelines
